Alan Bash
Vorstandsvorsitzender bei Zielbio, Inc.
Aktive Positionen von Alan Bash
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Zielbio, Inc.
 Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA. | Direktor/Vorstandsmitglied | 03.01.2023 | - |
| Vorstandsvorsitzender | 03.01.2023 | - |
Karriereverlauf von Alan Bash
Ehemalige bekannte Positionen von Alan Bash
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
| CHECKMATE PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.03.2022 | 31.05.2022 |
| Vorstandsvorsitzender | 01.03.2022 | - | |
| Präsident | 01.03.2022 | - |
Ausbildung von Alan Bash
| Georgetown University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| President | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Zielbio, Inc.
Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA. | Health Technology |
